Nghia V. Phan, Madeline Musacchio, Alex Pomeroy, Patricia P. Lassalle, Lee Stoner, FACSM. University of North Carolina at Chapel Hill, Chapel Hill, NC.

BACKGROUND: The number one cause of death in the United States is cardiovascular disease (CVD). The risk of CVD in individuals can be predicted by an increase in arterial stiffness. A widely used clinical measure of arterial wave reflection is pulse wave analysis (PWA). PWA estimates central systolic pressure (cSBP) and the augmentation index (Alx, a measure of arterial wave reflection). The SphygmoCor XCEL is the current non-invasive, “gold standard” scientific device used to measure PWA. Another reliable, valid, and potentially more cost-effective device to measure PWA is the VICORDER. However, no study has compared the agreement between the two devices for PWA outcomes. If the two devices are comparable, it would provide clinicians options for PWA measurements. The purpose of this study is to determine the agreement of PWA measurements between the SphygmoCor XCEL and the VICORDER. METHODS: We plan to recruit 30 male and female adults between the ages 18 to 45 to participate in this study. We will randomize participants on cuff placement for each device to the left or right side, and order of device use (SphygmoCor XCEL or VICORDER) for PWA. Participants will lay on a three-section table in supine posture after obtaining height and weight. Participants will rest for 20 minutes in supine posture. PWA values will be obtained using both the SphygmoCor XCEL and VICORDER in order based on device randomization generated before testing. After obtaining PWA values, participants will be passively moved to the second posture (25-degrees) and rest for 5 minutes. After resting, PWA measurements will be collected again. The agreement of PWA measurements between the two devices will be determined using the Pearson product-moment correlation (r) using the “rmcoor” package for R with a repeated measures correlation. Correlation values and 95% CIs will be calculated for each posture (supine and 25-degrees), PWA measures, and across aims using the “rmcorr” package for R. The agreement will be considered acceptable if the lower limit of the 95% CI for r exceeds 0.75 for both cSBP and Alx. ANTICIPATED RESULTS: It is hypothesized that the two devices (SphygmoCor XCEL and the VICORDER) will generate similar values for Alx and cSBP.

This document is currently not available here.